Search Results - "Maschan, M"

CAR-tropic extracellular vesicles carry tumor-associated antigens and modulate CAR T cell functionality by Ukrainskaya, V. M., Musatova, O. E., Volkov, D. V., Osipova, D. S., Pershin, D. S., Moysenovich, A. M., Evtushenko, E. G., Kulakovskaya, E. A., Maksimov, E. G., Zhang, H., Rubtsov, Y. P., Maschan, M. A., Stepanov, A. V., Gabibov, A. G.

“…Tumor-derived extracellular vesicles (EVs) are active contributors in metastasis and immunosuppression in tumor microenvironment. At least some of the EVs…”
Get full text

TCR-alpha/beta and CD19 depletion and treosulfan-based conditioning regimen in unrelated and haploidentical transplantation in children with acute myeloid leukemia by Maschan, M, Shelikhova, L, Ilushina, M, Kurnikova, E, Boyakova, E, Balashov, D, Persiantseva, M, Skvortsova, Y, Laberko, A, Muzalevskii, Y, Kazachenok, A, Glushkova, S, Bobrynina, V, Kalinina, V, Olshanskaya, Y, Baidildina, D, Novichkova, G, Maschan, A

“…We evaluated the depletion of TCR-alpha/beta cells from the graft of children with high-risk AML, who received transplantation from unrelated ( n =20) and…”
Get full text

Tracking T-cell immune reconstitution after TCR alpha beta /CD19-depleted hematopoietic cells transplantation in children by Zvyagin, I V, Mamedov, I Z, Tatarinova, O V, Komech, E A, Kurnikova, E E, Boyakova, E V, Brilliantova, V, Shelikhova, L N, Balashov, D N, Shugay, M, Sycheva, A L, Kasatskaya, S A, Lebedev, Y B, Maschan, A A, Maschan, M A, Chudakov, D M

“…alpha beta T-cell-depleted allogeneic hematopoietic cell transplantation holds promise for the safe and accessible therapy of both malignant and non-malignant…”
Get full text

Engineered Removal of PD-1 From the Surface of CD19 CAR-T Cells Results in Increased Activation and Diminished Survival by Kalinin, R. S., Ukrainskaya, V. M., Chumakov, S. P., Moysenovich, A. M., Tereshchuk, V. M., Volkov, D. V., Pershin, D. S., Maksimov, E. G., Zhang, H., Maschan, M. A., Rubtsov, Y. P., Stepanov, A. V.

“…CAR-T cell therapy is the most advanced way to treat therapy resistant hematologic cancers, in particular B cell lymphomas and leukemias, with high efficiency…”
Get full text

Tracking T-cell immune reconstitution after TCRαβ/CD19-depleted hematopoietic cells transplantation in children by Zvyagin, I V, Mamedov, I Z, Tatarinova, O V, Komech, E A, Kurnikova, E E, Boyakova, E V, Brilliantova, V, Shelikhova, L N, Balashov, D N, Shugay, M, Sycheva, A L, Kasatskaya, S A, Lebedev, Y B, Maschan, A A, Maschan, M A, Chudakov, D M

“…αβT-cell-depleted allogeneic hematopoietic cell transplantation holds promise for the safe and accessible therapy of both malignant and non-malignant blood…”
Get full text

Potential value of high-throughput single-cell DNA sequencing of Juvenile myelomonocytic leukemia: report of two cases by Volchkov, E. V., Khozyainova, A. A., Gurzhikhanova, M. Kh, Larionova, I. V., Matveev, V. E., Evseev, D. A., Ignatova, A. K., Menyailo, M. E., Venyov, D. A., Vorobev, R. S., Semchenkova, A. A., Olshanskaya, Yu. V., Denisov, E. V., Maschan, M. A.

“…Juvenile myelomonocytic leukemia (JMML) is a rare myeloproliferative disease of early childhood that develops due to mutations in the genes of the…”
Get full text

Efficacy of plerixafor in children with malignant tumors failing to mobilize a sufficient number of hematopoietic progenitors with G-CSF by Maschan, A A, Balashov, D N, Kurnikova, E E, Trakhtman, P E, Boyakova, E V, Skorobogatova, E V, Novichkova, G A, Maschan, M A

“…Mobilization of suitable amounts of PBSCs with granulocyte-CSF (G-CSF) can be difficult in children. We report the results of using plerixafor in pediatric…”
Get full text

First report of effective and feasible treatment of multifocal lymphangiomatosis (Gorham–Stout) with bevacizumab in a child by Grunewald, T.G.P., Damke, L., Maschan, M., Petrova, U., Surianinova, O., Esipenko, A., Konovalov, D., Behrends, U., Schiessl, J., Wörtler, K., Burdach, S., von Luettichau, I.

Get full text

The Role of Tumor-Derived Vesicles in the Regulation of Antitumor Immunity by Ukrainskaya, V M, Rubtsov, Y P, Knorre, V D, Maschan, M A, Gabibov, A G, Stepanov, A V

“…In this article, we present a comprehensive, updated, and elucidative review of the current knowledge on the function played by tumor-derived vesicles (TDVs)…”
Get full text

Reliability of immune receptor rearrangements as genetic markers for minimal residual disease monitoring by Nazarov, V I, Minervina, A A, Komkov, A Y, Pogorelyy, M V, Maschan, M A, Olshanskaya, Y V, Zvyagin, I V, Chudakov, D M, Lebedev, Y B, Mamedov, I Z

Get full text

Adoptitive immunotherapy with genetically engineered T lymphocytes modified to express chimeric antigen receptors by Pavlova, A. А., Maschan, M. А., Ponomarev, V. B.

“…Significant mortality due to oncological diseases as a whole, and oncohematological diseases in particular, motivates scientific and medical community to…”
Get full text

Molecular Approaches to Safe and Controlled Engineered T-cell Therapy by Kalinin, R S, Petukhov, A V, Knorre, V D, Maschan, M A, Stepanov, A V, Gabibov, A G

“…Chimeric antigen receptor-modified T-cell therapy (CAR-T therapy) is one of the fastest developing areas of immuno-oncology. Over the past decade, it has…”
Get full text

Barnase-barstar Specific Interaction Regulates Car-T Cells Cytotoxic Activity toward Malignancy by Kalinin, R. S., Shipunova, V. O., Rubtsov, Y. P., Ukrainskay, V. M., Schulga, A., Konovalova, E. V., Volkov, D. V., Yaroshevich, I. A., Moysenovich, A. M., Belogurov, A. A., Telegin, G. B., Chernov, A. S., Maschan, M. A., Terekhov, S. S., Knorre, V. D., Khurs, E., Gnuchev, N. V., Gabibov, A. G., Deyev, S. M.

“…The development of CAR-T specific therapy made a revolution in modern oncology. Despite the pronounced therapeutic effects, this novel approach displayed…”
Get full text

Hematopoietic stem cell transplantation with alpha/beta T-lymphocyte depletion and short course of eculizumab in adolescents and young adults with paroxysmal nocturnal hemoglobinuria by Shasheleva, D A, Maschan, A A, Shelikhova, L N, Petrova, U N, Kurnikova, E E, Illarionova, O I, Boyakova, E V, Novichkova, G A, Maschan, M A

“…The main goal is to optimize hematopoietic stem cell transplantation (HSCT) approach among adolescents and young adults with paroxysmal nocturnal…”
Get full text

The role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia: literature review and own experience by Dyakonova, Y Y, Bydanov, O I, Popov, A M, Olshanskaya, Y V, Boichenko, E G, Aleynikova, O V, Maschan, M A, Shelikhova, L N, Litvinov, D V, Khachatryan, L A, Ponomareva, N I, Fechina, L G, Novichkova, G A, Pashanov, E D, Karachunskiy, A I

“…The analysis of experience of nelarabine use in refractory/relapsed T-cell acute lymphoblastic leukemia (T-ALL) depending on the immunophenotype and the line…”
Get full text

Use of crizotinib for refractory ALK-positive lymphomas by Shelikhova, L N, Fominykh, V V, Abramov, D S, Myakova, N V, Maschan, M A, Maschan, A A

“…To evaluate the safety and efficacy of crizotinib used in pediatric patients with relapsed or refractory ALK-positive anaplastic large-cell lymphoma (ALCL)…”
Get full text

Protocol AML-MM-2000 treatment results of unfavorable prognostic group in children with acute myeloid leukemia by N. P. Kirsanova, O. V. Aleinikova, A. M. Kustanovich, T. V. Savitskay, R. I. Yutskevich, E. V. Volochnik, L. V. Baidun, Yu. E. Mareiko, Yu. S. Strongin, N. V. Minakovskay, N. V. Migal, I. V. Proleskovskay, I. V. Emelyanova, O. V. Karas, A. G. Drekov, M. M. Maschan, D. V. Litvinov, N. V. Myakova, E. V. Skorobogatova, D. D. Baidildina, I. I. Kalinina, G. G. Solopova, E. V. Suntsova, U. N. Petrova, L. A. Hachatryan, M. M. Scheider, A. A. Maschan

“…Protocol AML-MM-2000 treatment results of unfavorable prognostic group in children with primary acute myeloid leukemia (AML) in Russia and Belarus are…”
Get full text

CD-19-directed immunotherapy resistance mechanisms of B-precursor acute lymphoblastic leukemia by Glukhanyuk, E. V., Stepanov, A. V., Popov, A. M., Maschan, M. A.

“…Immunotherapy is the most rapidly evolving field in clinical malignant hematology. Targeting of the B-lineage surface antigen CD19 in B-lineage acute…”
Get full text

Clinical characteristics and prognostic significance of extramedullary involvement in childhood acute myeloid leukemia by Ignatova, A. K., Kalinina, I. I., Venev, D. A., Salimova, T. Yu, Evseev, D. A., Sadovskaya, M. N., Goronkova, O. V., Matveev, V. E., Petrova, U. N., Antonova, K. S., Baydildina, D. D., Dubrovnaya, M. E., Konyukhova, T. V., Olshanskaya, Yu. V., Abramov, D. S., Maschan, M. A., Novichkova, G. A., Maschan, A. A.

“…Background . Extramedullary infiltration (EI) is relatively common in children with acute myeloid leukemia (AML) (up to 20-25 %). However, its clinical and…”
Get full text

Features of Development and Course of Disseminated Intravascular Coagulation Syndrome During Surgical Interventions in Children with Oncological Diseases by Leonov, N. P., Schukin, V. V., Novichkova, G. A., Maschan, M. A., Ataullakhanov, F. I., Yashin, S. S., Zeynalov, A. M., Spiridonova, Е. A.

“…Coagulopathy always accompanies blood loss, and its transformation into disseminated intravascular coagulation syndrome (DIC) is associated with increased…”
Get full text